

(-)

()

(% /)

(% /)

(% /)

(% /)

)

()

(%)

()

(

(% /)

(%)

(% /)

(.)

-

(.)

-

(.)

(.)

:

/

(

)

-

(.)

)

(

-

()

(.)

(

)

)

(

Bactec ()

) % /

()

(
(P=0.002)

() %

SPSS

()

%

% /

Bactec

(Solid tumor)

(% /)

(% /)

() ;

() .

- (% /)

- (% /)

()

- (% /)

()

% /

(% /)

%

% /

()

% /

(A)

B

()

- ()

()

()

- ()

()

(%)

(% /)

%
% /

H₂

Archive of SID

REFERENCES:

1. Freifeld AG, Walsh T, Marshall D, et al: Monotherapy for fever and neutropenia, a randomized comparison of ceftazidime versus imipenem. *J. Clin. Oncology*. 1995, 13: 165-176.
2. Ben E. Depauw, J. Peter Donnelly. Infections in the Immunocompromised host. in: Mandell's Principle and Practice of Infectious disease. 2000, 5th edition. Churchill Livingstone Co.
3. The EORTC International Antimicrobial therapy cooperative Group: Gram-positive bacteremia in granulocytopenic cancer patients. *Eur.J.cancer*. 1990, 26: 569-574.
4. Michel P, Glauser and Thierry calandra. Infection in patients with hematologic malignancies in: Management of infections in immunocompromised patients. First edition. 2000, W.B.Saunders.
5. Todeschini G, Franchini M, Tecchio C, et al: Improved prognosis of pseudomonas aeruginose bacteremia in 127 Consecutive neutropenic patients with hematologic malignancies. *Int. J. Infect. Dis.* 1999, 3(2): 99-104
6. Meri H.M. Balawi I.A, et al: Fever and granulocytopenia in children with acute lymphoblastic leukemia under induction therapy. *Saudi. Med. J.* 2001. 22(5): 423-427.
7. Fleischhack G, Hartman C. Simon A. et al: Meropenem versus ceftazidime as empirical mono therapy in febrile neutropenia of peditarc patients with cancer. *J. Antimicrob. Chemother.* 2001, 47(6): 841-853.
8. Victor M. Aquino. Alberto Pappo, George R. Buchanan, et al: The changing epidemiology of bacteremia in neutropenic children with cancer. *Pediatr. Infect. Dis.J.* 1995. 14: 140-143.
9. Chatzinikolaou. I, Abi-Said D, Bodey G.P, et al: Recent experience with pseudomonas aeruginosa bacteremia in patients with cancer. *Arch. Intern. Med.* 2000, 160(4): 501-509.
10. Walter T. Hughes, Gerald P. Bodey, Donald Armstrong: 1997 Guidline for the use of antimicrobial agents in neutropenic patients with unexplained fever. *Clin. Infect. Dis.* 1997,25: 551-573.
11. De Pauw B.E, Deresinski S.C, Feld R, et al: ceftazidime compared with piperacillin and tobramycin for empiric treatment of fever in neutropenic patients with cancer. *Ann Intern. Med.* 1994, 120: 834-844.
12. Munyi S.T, Macharia W.M, Alwar AJ, et at: Screening for urinary tract infection in children with cancer. *East. Afr. Med. J.* 1998, 75(5): 264-267.
13. Noriega L.M, Vander Auwera P, Phan M, et al: Anaerobic bacteremia in a cancer center. *Support. Care. Cancer.* 1993, 1: 250-255.
14. Lehmbacher T, Venzon D, de Hass M, et al: Assesment of measuring circulating levels of Interleukin-6, Interleukin-8, C-reactive protein, Soluble FC gamma receptor type III, and manose binding protein in febrile children with cancer and neutropenia. *Clin. Infect. Dis.* 1999, 29(2): 414-419.
15. de Bont E.S., Vellenga E, Swaanenburg I.C, et al: plasma IL-8 and IL-6levels can be used to defme a group with low risk of septicemia among cancer patients with fever and neutropenia. *Br.I. Haematol.* 1999, 107(2): 375-380.

(% /)	% /		
(% /)	% /		
(% /)	% /		
(% /)	% /		
(% /)	% /		
(% /)	% /		()
(% /)	% /		()
(% /)	% /		
(% /)	% /		
(% /)	% /		
(% /)	% /		
(% /)	% /		
(% /)	% /		

Archive of SID